T-ALL Gene-Edited Cell Lines for Drug Discovery and Research

T-cell acute lymphoblastic leukemia (T-ALL) accounts for approximately 15-25% of ALL cases in children and up to 25% in adults. According to the World Health Organization (WHO) classification of tumours of haematopoietic and lymphoid tissues (5th edition, 2022), T-ALL is an aggressive hematologic malignancy. The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program reports a 5-year survival rate of approximately 85% for children but only 50-60% for adults, with significant disparities based on age and cytogenetic risk groups. Key risk factors include male sex, genetic syndromes (e.g., ataxia telangiectasia), and prior exposure to ionizing radiation. Relapsed/refractory T-ALL remains a major clinical challenge with poor outcomes.

T-ALL is an ideal model for mechanistic studies due to its well-defined genetic subtypes, rapid disease progression, and availability of public datasets from The Cancer Genome Atlas (TCGA) and COSMIC. Open questions include the role of NOTCH1 signaling in leukemogenesis, mechanisms of chemoresistance, and identification of novel therapeutic targets. The disease's reliance on specific oncogenic drivers (e.g., NOTCH1, PTEN, FBXW7) makes it highly amenable to CRISPR-based functional genomics.

• • The pathogenesis of T-ALL involves several key pathways:
• • NOTCH1 signaling: Gain-of-function mutations in NOTCH1 (present in ~60% of cases) lead to constitutive activation of the NOTCH pathway, promoting cell proliferation and survival.
• • PI3K/AKT/mTOR pathway: Loss of PTEN (10-15%) or activating mutations in PI3K result in uncontrolled growth.
• • Cell cycle regulation: Mutations in CDKN2A (p16INK4a/p14ARF) occur in >70% of cases, leading to loss of cell cycle control.
• • Transcription factor deregulation: Overexpression of TAL1, LMO1, LMO2, or TLX1/HOX11 drives aberrant T-cell development.

Data from TCGA (Cancer Genome Atlas Network, Nature 2012) and COSMIC (v99, 2024).

• • Key signaling networks in T-ALL include:
• • NOTCH pathway: NOTCH1, JAG1, DLL4, HES1, MYC
• • PI3K/AKT/mTOR: PTEN, PIK3CA, AKT1, MTOR, S6K1
• • MAPK/ERK: KRAS, NRAS, BRAF, MEK1/2, ERK1/2
• • JAK/STAT: JAK1, JAK3, STAT5B, IL7R
• • Cell cycle: CDKN2A, CDK4, CDK6, RB1, E2F1

Organoid models derived from patient samples are emerging as 3D culture systems that better recapitulate the bone marrow microenvironment and allow for drug testing and CRISPR editing.

• • Patient-derived xenograft (PDX) models: Immunodeficient mice (NSG) engrafted with primary T-ALL cells; used for drug efficacy and resistance studies.
• • Genetically engineered mouse models (GEMMs): Conditional NOTCH1 activation or PTEN deletion in T-cell progenitors (e.g., Lck-Cre).
• • Induced models: Retroviral or lentiviral transduction of oncogenes (e.g., TAL1, LMO2) in hematopoietic stem cells followed by transplantation.

CRISPR/Cas9 technology enables the generation of isogenic cell lines with precise genetic modifications. For T-ALL, commonly engineered models include TP53 knockout, PTEN knockout, NOTCH1 knock-in (activating mutations), and CDKN2A deletion. These sequence-verified, commercially available models allow researchers to study gene function in a controlled background, validate drug targets, and model resistance mechanisms. Isogenic pairs (e.g., wild-type vs. knockout) are particularly valuable for phenotypic screening and biomarker discovery.

CRISPR knockout and knock-in cell lines are used to validate the role of candidate genes in T-ALL. For example, PTEN knockout in JURKAT cells confirms its tumor suppressor function and sensitizes cells to PI3K inhibitors. NOTCH1 knock-in models demonstrate the oncogenic potential of specific mutations. Pooled CRISPR screens in T-ALL cell lines have identified essential genes (e.g., MYC, CDK6) and synthetic lethal interactions.

Isogenic cell line pairs (e.g., TP53 wild-type vs. knockout) are used in high-throughput drug screens to identify genotype-specific sensitivities. Resistance models are generated by chronic exposure to drugs (e.g., dexamethasone, doxorubicin) or by introducing resistance mutations via CRISPR (e.g., NOTCH1 PEST domain mutations conferring resistance to gamma-secretase inhibitors).

CRISPR-based synthetic lethality screens in T-ALL cell lines identify genetic dependencies that can serve as biomarkers for targeted therapy. For example, loss of PTEN creates vulnerability to AKT inhibitors, and CDKN2A deletion sensitizes cells to CDK4/6 inhibitors. These findings are validated using isogenic models and patient-derived samples.